Latest news with #EyeQ
Business Insider
09-07-2025
- Business
- Business Insider
Mobileye sees Q2 revenue $502M-$506M, consensus $466.4M
In a regulatory filing, the company has commented on Recent Developments impacting its operations stating: 'Events in Israel: On June 13, 2025, Israel launched a preemptive attack on Iran, to which Iran responded with ballistic missile and drone attacks. On June 23, 2025, Israel and Iran agreed to a ceasefire, although there is no assurance that the ceasefire will continue. How long and how severe the current conflict may become is unknown at this time, and any continued clash among Israel and Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict. The Company expects that the current conflict as well as the security escalation in Israel will not have a material impact on its business results in the short term. The Company has a business continuity plan in place to address a range of scenarios, including potential escalations, which it believes has proven effective over the past 18 months. However, since these are events beyond the Company's control, their continuation or cessation may affect the Company's expectations. The Company continues to monitor political and military developments closely and examine the consequences for its operations and assets. Agreement with TSMC (TSM): The Company has a long-standing relationship with STMicroelectronics to manufacture its EyeQ products. As part of an effort to establish redundancy and better control of its supply chain, the Company has sought additional qualified suppliers, and it has recently entered into an agreement with TSMC under which it will manufacture components of the Company's imaging radar and some of its future generations of its EyeQ product, and potentially other future products.'
Business Wire
30-05-2025
- Business
- Business Wire
MOBILEYE GLOBAL INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Mobileye Global Inc.'s Directors and Officers for Breach of Fiduciary Duties
NEW YORK--(BUSINESS WIRE)-- Scott+Scott Attorneys at Law LLP ('Scott+Scott'), an international securities and consumer rights litigation firm, is investigating whether Intel Corporation ('Intel'), as well as the leadership of Mobileye Global Inc. ('Mobileye') (NASDAQ: MBLY), breached their fiduciary duties to Mobileye and its shareholders. Scott+Scott is investigating whether Intel, as controlling stockholder of Mobileye, as well as members of the Mobileye board of directors or senior management, failed to manage Mobileye in an acceptable manner, or enriched themselves at Mobileye's expense, in breach of their fiduciary duties to Mobileye, and whether Mobileye and its shareholders have suffered damages as a result. On January 4, 2024, Mobileye announced that it had 'become aware' of an accumulation of excess inventory with its customers, that 'lower-than-expected volumes' in the EyeQ area of its business would temporarily affect profitability and lowered its revenue guidance for 2024 accordingly. On August 1, 2024, Mobileye announced it was further reducing its 2024 revenue guidance, with the channel stuffing issue as the cause. On this news, Mobileye stock fell to $16.28/share. In June 2023, Intel, the controlling stockholder of Mobileye, sold 38.5 million shares of Mobileye at $42/share, getting over $1.6 billion in proceeds. What You Can Do – If you own shares of Mobileye, you may have legal claims against Intel, as well as Mobileye's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@ About Us Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoings, including securities law and shareholder violations. With more than 100 attorneys in nine offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit Attorney Advertising
Yahoo
13-05-2025
- Automotive
- Yahoo
Here's Why You Should Retain Mobileye Stock in Your Portfolio Now
Mobileye Global Inc. MBLY, a leader in autonomous driving and driver-assistance technologies, is likely to benefit from increasing demand for ADAS (advanced driver assistance systems) and autonomous driving features amid rising operating expenses. Let us see why you should retain this Zacks Rank #3 (Hold) stock in your portfolio. The rising demand for ADAS and autonomous driving features is fueling Mobileye's prospects. Its cutting-edge technology enhances automotive safety, productivity and vehicle utilization. As the auto industry accelerates toward self-driving vehicles, the company's innovative solutions like Supervision, Chauffeur, Drive and EyeQ strengthen its portfolio. MBLY is still securing new ADAS deals with its main customers and also finding promising opportunities with new clients. A major tailwind for Mobileye is the growing adoption of multi-camera setups, driven by stricter safety regulations and the push for hands-free highway driving in mass-market expects revenues and adjusted operating income to rise year over year in 2025. It estimates revenues in the range of $1.69-$1.81 billion, up from $1.65 billion recorded in 2024. The revenue forecast is based on EyeQ unit sales ranging from 32-34 million units. For the second quarter of 2025, it expects revenues to be up about 7% year over partnerships and significant design wins are pivotal to Mobileye's robust growth. With ZEEKR as its launch partner and design wins with automakers like Porsche, FAW, Mahindra and other major OEMs in 2023, Mobileye's prospects are soaring. In March 2024, Volkswagen deepened its partnership with Mobileye to integrate SuperVision and Chauffeur technologies for partially and highly automated driving into series production. In March 2025, Volkswagen announced a collaboration with Mobileye to enhance safety and driving comfort in the former's upcoming MQB-based vehicle strong balance sheet, with $1.51 billion of cash/cash equivalents and zero debt as of March 25, 2025, also instills investors' confidence. This financial flexibility allows MBLY to tap into growth opportunities. Mobileye expects production volume from its top 10 customers to be down 3-7% year over year in 2025. Its shipments of assisted driving technology to China are under pressure due to stiff competition from local players offering similar self-driving software at lower costs. High operating expenses, caused by rising employee compensation and increased military reserve investments, will likely clip operating income. Even though there will be savings from winding down the LIDAR unit, headcount-related cost pressures will keep overall operating expenses elevated, hindering potential income growth. MBLY expects 7% year-over-year growth in adjusted operating expenses in 2025. Some better-ranked stocks in the auto space are Hesai Group HSAI, Ferrari N.V. RACE and Standard Motor Products, Inc. SMP. HSAI & RACE sport a Zacks Rank #1 (Strong Buy) each, while SMP carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks Zacks Consensus Estimate for HSAI's 2025 earnings indicates year-over-year growth of 336.36%. EPS estimates for 2026 have improved 12 cents in the past 30 Zacks Consensus Estimate for RACE's 2025 sales and earnings implies year-over-year growth of 12.37% and 4.8%, respectively. EPS estimates for 2025 and 2026 have improved 30 cents and 36 cents, respectively, in the past seven Zacks Consensus Estimate for SMP's 2025 sales and earnings implies year-over-year growth of 17.1% and 12.62%, respectively. EPS estimates for 2025 and 2026 have improved 6 cents and 2 cents, respectively, in the past 30 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Standard Motor Products, Inc. (SMP) : Free Stock Analysis Report Mobileye Global Inc. (MBLY) : Free Stock Analysis Report Ferrari N.V. (RACE) : Free Stock Analysis Report Hesai Group Sponsored ADR (HSAI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
26-03-2025
- Health
- Yahoo
25 Years of Trust, Quality, and Health: SFI Health™ celebrates Equazen® milestone, the brand of food supplements developed to support cognitive needs
- From a pioneering intuition on the benefits of essential fatty acids for the human brain to becoming a global brand trusted by families and healthcare professionals LUGANO, Switzerland, March 26, 2025--(BUSINESS WIRE)--SFI Health™ is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements. The story of Equazen® began in 1999 in the UK with Prof. Horrobin's groundbreaking research. Guided by his intuition, he researched certain pediatric cognitive function disorders stemming from a lack of essential fatty acids and their precursors. This insight led to the development of the first Equazen® product, originally known as Eye Q. The product featured a unique combination of essential fatty acids, setting the foundation for Equazen®'s evolution while aligning with the company's core philosophy: to harness the power of naturally sourced ingredients and adopt a pharma-quality approach to food supplements. Since the publication of its first clinical evidence in 2005, Equazen® has been supported by over two decades of clinical trials. As a result, the brand is trusted globally by business partners, families and healthcare professionals to enhance learning capabilities, concentration, and overall cognitive well-being. At the same time, Equazen® has evolved into multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. One of the latest innovations is Equazen® Jelly, which combines the unique blend of essential fatty acids with a fruity flavor designed to appeal to picky eaters. Additionally, its patent-protected technology ensures the jelly is easy to swallow and promotes better natural absorption. Matthew Brabazon, GM of SFI Heath™ EMEA, the regional entity of SFI Health™, commented: "It's been an incredible journey watching Equazen® grow over the past 25 years to become a trusted brand globally. Looking ahead, we remain focused on the future and have exciting plans to continue bringing innovation to the market." Zbyszek Czop, Managing Director of Qpharma Sp. z o.o., distributor of Equazen® in Poland said: "Earning the trust of doctors through the positive results of clinical studies on Equazen® is incredibly gratifying. Healthcare professionals now believe that Equazen® can make a meaningful difference for children, particularly those with behavioral disorders." Kirsten Jorsal, Founder of Novasel EU, distributor of Equazen® in Denmark added: "Equazen® is a unique fatty acid supplement, distinguished by its balanced blend of polyunsaturated fatty acids, with a notably higher EPA content compared to DHA. Along with its strong clinical documentation, it stands apart from other fish oil supplements. Working with this product for so many years has been both rewarding, and receiving feedback from satisfied families has been truly fulfilling." A deep knowledge of consumers' needs continues to guide the brand and inspires future innovations. The Equazen® range is proudly available in 30 countries across all continents, and the company is dedicated to expanding its reach, ensuring more consumers worldwide can benefit from its offerings. About SFI Health™ SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing. Guided by the belief in the healing potential of natural products, SFI Health™ combines a rigorous pharma-based approach with the benefits of naturally sourced solutions. An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa. SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide. For more information go to or follow us SFI Health on LinkedIn. About Equazen® Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain's potential across all life stages. Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development. Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers. Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years. Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential. For more info visit View source version on Contacts For more information SFI Health™ EMEA Contact Elisabetta Bianchie-mail address: Sign in to access your portfolio
Yahoo
30-01-2025
- Automotive
- Yahoo
Mobileye forecasts downbeat annual revenue as China weakness persists
(Reuters) - Mobileye forecast full-year revenue below Wall Street expectations on Thursday, anticipating fewer shipments of its assisted driving technology to China amid stiff competition from local players. The company expects fiscal 2025 revenue between $1.69 billion and $1.81 billion, compared with the average analyst estimate of $1.94 billion, according to data compiled by LSEG. Shipments for the company's technology to China have been pressured by competition from domestic firms developing similar self-driving software at lower costs. In December, Mobileye said its major automotive customers were losing market share in the country as domestic manufacturers are now offering less-expensive battery vehicles in the region. Shipment volumes of Mobileye's chips in China are improving compared with 2024 but still remain sluggish, company executives said on a post-earnings call on Thursday. Earlier this month, the Chinese government reintroduced some EV subsidies to encourage citizens to adopt environment-friendly vehicles. Mobileye reported fourth-quarter revenue of $490 million, beating estimates of $477.8 million. Although the company beat market expectations for revenue, the numbers fell 23% from a year earlier due to less demand for its EyeQ chips as major customers work through excess supply. Mobileye said on Friday that testing of its assisted driving tech with potential customers "will bear fruit in 2025". The company doesn't see a trend where legacy automakers develop their own in-house driver assistance systems owing to many firms rethinking their electrification strategy as EV demand slows, Mobileye added. On an adjusted basis, the company earned 13 cents per share in the fourth quarter, compared with estimates of 11 cents. It also reported a 30% fall in gross profit in the quarter. Sign in to access your portfolio
